The oral phosphodiesterase 4 inhibitor apremilast (Otezla) is indicated for the treatment of oral ulcers associated with Behçet's disease in some countries, including the USA (where it is the first agent approved for the disease) and Japan. In phase 2 and 3 trials in adults with this chronic and debilitating disorder, 12 weeks of treatment with apremilast 30 mg twice daily reduced the number and pain of oral ulcers and disease activity relative to placebo, with these clinical benefits being accompanied by improvements in health-related quality of life (HR-QOL). Benefits of apremilast were seen regardless of baseline patient/disease characteristics and in Japanese patients, and were sustained over up to 64 weeks of treatment. Apremilast was generally well tolerated, with gastrointestinal adverse events being among the most common tolerability issues. Emerging real-world data also support the drug's use in this setting. Thus, for patients with oral ulcers associated with Behçet's disease, apremilast provides an effective and generally well tolerated approved treatment option.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s40265-019-01253-3 | DOI Listing |
Indian J Sex Transm Dis AIDS
December 2024
Department of Dermatology, Venereology and Leprosy, Government Medical College and S.S.G. Hospital, Vadodara, Gujarat, India.
Behcet syndrome (BS) is a chronic relapsing multisystem vasculitis with skin findings with an important contribution of genetics. Here, we present a case of a 16-year-old male with a complaint of recurrent genital, and oral ulceration with skin lesions and a history of recurrent thrombophlebitis at the sites of venepuncture. There were no systemic manifestations.
View Article and Find Full Text PDFDEN Open
April 2025
Department of Gastroenterology, Hematology, and Clinical Immunology Hirosaki University Graduate School of Medicine Aomori Japan.
Severe esophageal strictures resulting from chemoradiotherapy pose persistent therapeutic challenges despite the availability of treatments such as endoscopic balloon dilation and medications. Hyperbaric oxygen therapy (HBOT) has emerged as a promising treatment option for refractory radiation-induced injury to several organs. Herein, we present the case of a 79-year-old male patient with refractory radiation-induced ulcerative esophageal strictures after chemoradiotherapy.
View Article and Find Full Text PDFInt J Womens Health
January 2025
Division of Breast Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu City, Sichuan Province, People's Republic of China.
Purpose: Corticosteroids are recommended as a first-line treatment for idiopathic granulomatous mastitis (IGM), a disease that usually occurs in young women. Corticosteroid phobia is a fear of corticosteroids and one of the main reasons for poor treatment compliance. Despite the increasing recognition of corticosteroid phobia, there has been a lack of studies on this issue in IGM.
View Article and Find Full Text PDFRiga-Fede disease (RFD) is a rare, benign condition marked by traumatic ulceration on the tongue's ventral side in infants. It arises from friction between the tongue and lower incisors during sucking, potentially worsening into a keratinized lesion if the cause is not addressed. This report details the case of a 1-year-6-month-old male with hydrocephalus, cleft palate, corpus callosum dysgenesis, neuropsychomotor developmental delay, and tracheostomy and gastrostomy needs.
View Article and Find Full Text PDFJ Int Med Res
January 2025
Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Behçet's disease (BD) is a rare systemic vasculitis that is characterized by recurrent oral and genital ulcers, uveitis, and skin lesions. Although neurological involvement is a known complication, ischemic stroke remains uncommon. Herein, we report a 37-year-old Kuwaiti woman who experienced recurrent ischemic stroke with no traditional risk factors.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!